Position in ENGN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$284,706
-$798,553 QoQ
Shares Held
164,570
+3.5% QoQ
Ownership
0.246%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#32
of 60 holders
Holding Since
Sep 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ENGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026TWO SIGMA INVESTMENTS, LP holds $7,273,657,992 across 342 Biotechnology names. ENGN ranks #276 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,875,937 | $564,713,315 | |
| 2 | MRNA |
Moderna, Inc.
|
7,193,530 | $503,762,905 | |
| 3 | IONS |
Ionis Pharmaceuticals Inc
|
6,252,342 | $495,748,197 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
656,124 | $409,119,558 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
4,722,185 | $351,708,338 | |
| 6 | EXEL |
Exelixis, Inc.
|
4,209,861 | $229,058,537 | |
| 7 | INCY |
Incyte Corp
|
2,003,559 | $227,123,448 | |
| 8 | ARGX |
Argenx SE
|
185,638 | $172,229,367 |
All Filings in ENGN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $284,706 | 164,570 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $1,083,259 | 159,069 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,458,453 | 161,512 | Shares | Sole | 2026-02-17 | |
| 2025-03-31 | $70,927 | 15,832 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $238,508 | 35,866 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $261,498 | 39,621 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||